A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Study For Previously Treated Patients Of Multiple Myeloma Therapy Using Carfilozmib, Pomalidomide, and Dexamethasone
Sponsor: Academic Myeloma Consortium AMyC
Enrolling: Male and Female Patients
IRB Number: AAAJ2354
U.S. Govt. ID: NCT01464034
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: This is a research study for subjects who have been diagnosed with multiple myeloma, a cancer of plasmacells (a type of immune cell that produce antibodies) in the bone marrow, that has returned (relapsed) or has not responded (refractory) to your most recent treatment regimen.The subject's disease has also progressed after prior treatment with lenalidomide (Revlimid).The main purpose of this research study is to evaluate the safety and determine the maximum tolerated dose of two investigational new drugs, carfilzomib and pomalidomide, in combination with dexamethasone in subjects with relapsed or refractory multiple myeloma.
This study is closed
Suzanne Lentzsch, MD
Do You Qualify?
Do you have multiple myeloma? Yes No
Have you received prior lenalidomide therapy that did not work? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton